

CTI BIOPHARMA CORP  
Form 4  
September 24, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Plunkett Matthew

(Last) (First) (Middle)

3101 WESTERN AVENUE, SUITE 600

(Street)

SEATTLE, WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
CTI BIOPHARMA CORP [CTIC]

3. Date of Earliest Transaction (Month/Day/Year)  
09/22/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
\_X\_ Officer (give title below) \_\_\_ Other (specify below)

EVP, Corporate Development

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_X\_ Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code V	Amount or Price (A) or (D)		
Common Stock	09/22/2014		S <sup>(1)</sup>	500	D	\$ 2.49	545,103 D
Common Stock	09/22/2014		S <sup>(1)</sup>	600	D	\$ 2.5	544,503 D
Common Stock	09/22/2014		S <sup>(1)</sup>	1,500	D	\$ 2.51	543,003 D
Common Stock	09/22/2014		S <sup>(1)</sup>	799	D	\$ 2.52	542,204 D
Common Stock	09/22/2014		S <sup>(1)</sup>	3,500	D	\$ 2.53	538,704 D

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	300	D	\$ 2.54	538,404	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	300	D	\$ 2.55	538,104	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	981	D	\$ 2.56	537,123	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	3,000	D	\$ 2.57	534,123	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	27,400	D	\$ 2.58	506,723	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	2,793	D	\$ 2.59	503,930	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	3,901	D	\$ 2.6	500,029	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	1,408	D	\$ 2.61	498,621	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	2,635	D	\$ 2.62	495,986	D
Common Stock	09/22/2014	<u>S<sup>(1)</sup></u>	2,200	D	\$ 2.63	493,786	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	3,900	D	\$ 2.5	489,886	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	15,728	D	\$ 2.51	474,158	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	722	D	\$ 2.52	473,436	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	2,600	D	\$ 2.53	470,836	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	3,300	D	\$ 2.54	467,536	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	14,118	D	\$ 2.55	453,418	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	9,250	D	\$ 2.56	444,168	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	600	D	\$ 2.57	443,568	D
Common Stock	09/23/2014	<u>S<sup>(1)</sup></u>	1,600	D	\$ 2.58	441,968	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not**

SEC 1474  
(9-02)

required to respond unless the form displays a currently valid OMB control number.

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121			EVP, Corporate Development	

## Signatures

Louis A. Bianco Attorney-in-fact For: Matthew Plunkett  
Date: 09/24/2014

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.